Boston Scientific Corporation
BSX
$100.94
$2.022.04%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.60% | 15.65% | 13.64% | 12.74% | 12.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.60% | 15.65% | 13.64% | 12.74% | 12.29% |
| Cost of Revenue | 20.47% | 16.82% | 15.31% | 11.55% | 9.69% |
| Gross Profit | 16.32% | 15.13% | 12.90% | 13.28% | 13.48% |
| SG&A Expenses | 15.30% | 15.62% | 11.66% | 14.20% | 14.82% |
| Depreciation & Amortization | 3.38% | 2.44% | 3.56% | 3.96% | 3.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.25% | 14.43% | 11.92% | 11.65% | 11.04% |
| Operating Income | 24.22% | 21.64% | 22.32% | 18.32% | 18.79% |
| Income Before Tax | 14.90% | 17.38% | 41.83% | 50.28% | 74.21% |
| Income Tax Expenses | 10.94% | -36.01% | -46.74% | -28.60% | -11.09% |
| Earnings from Continuing Operations | 15.88% | 45.48% | 100.00% | 96.45% | 128.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 600.00% | -- | -- | -- | -- |
| Net Income | 16.25% | 45.81% | 100.44% | 96.67% | 128.37% |
| EBIT | 24.22% | 21.64% | 22.32% | 18.32% | 18.79% |
| EBITDA | 18.22% | 16.00% | 16.64% | 13.99% | 13.95% |
| EPS Basic | 16.72% | 48.46% | 108.22% | 104.44% | 140.43% |
| Normalized Basic EPS | 28.90% | 23.30% | 25.29% | 18.73% | 36.67% |
| EPS Diluted | 16.87% | 47.85% | 105.95% | 102.64% | 139.95% |
| Normalized Diluted EPS | 28.61% | 23.05% | 25.09% | 18.58% | 36.53% |
| Average Basic Shares Outstanding | 1.27% | 1.69% | 2.13% | 2.00% | 1.57% |
| Average Diluted Shares Outstanding | 1.53% | 1.90% | 2.30% | 2.14% | 1.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -1.00% | -1.00% | -0.87% | -0.78% |